Circulating Virus–Host Chimera DNAs in the Clinical Monitoring of Virus‐Related Cancers
Journal
Cancers
Journal Volume
14
Journal Issue
10
Date Issued
2022-05-01
Author(s)
Abstract
The idea of using tumor‐specific cell‐free DNA (ctDNA) as a tumor biomarker has been widely tested and validated in various types of human cancers and different clinical settings. ctDNA can reflect the presence or size of tumors in a real‐time manner and can enable longitudinal monitoring with minimal invasiveness, allowing it to be applied in treatment response assessment and recurrence monitoring for cancer therapies. However, tumor detection by ctDNA remains a great challenge due to the difficulty in enriching ctDNA from a large amount of homologous non‐tumor cell‐free DNA (cfDNA). Only ctDNA with nonhuman sequences (or rearrangements) can be se-lected from the background of cfDNA from nontumor DNAs. This is possible for several virus-related cancers, such as hepatitis B virus (HBV)‐related HCC or human papillomavirus (HPV)‐re-lated cervical or head and neck cancers, which frequently harbor randomly integrated viral DNA. The junction fragments of the integrations, namely virus–host chimera DNA (vh‐DNA), can repre-sent the signatures of individual tumors and are released into the blood. Such ctDNA can be en-riched by capture with virus‐specific probes and therefore exploited as a circulating biomarker to track virus‐related cancers in clinical settings. Here, we review virus integrations in virus‐related cancers to evaluate the feasibility of vh‐DNA as a cell‐free tumor marker and update studies on the development of detection and applications. vh‐DNA may be a solution to the development of specific markers to manage virus‐related cancers in the future.
Subjects
circulating tumor DNA (ctDNA) | liquid biopsy | virus DNA integration | virus–host chimera DNA (vh‐DNA)
Type
other